BioSpace News Archive

BioTheryX, Inc., a clinical-stage company focused on degrading proteins to create life-saving medicines, today announced the expansion of its Scientific Advisory Board (SAB) with the appointment of Brenda Schulman , Ph.D., Director of the Department of Molecular Machines and Signaling at Max Planck Institute of Biochemistry,

-- Results demonstrate NKTR-255’s differentiated pharmacologic profile versus precomplexed IL-15 agonists, supporting its potential as a potent immunotherapy agent --

Company Supports Increased Commercial Growth with Appointment of Seasoned Medtech Executive to Chief Financial Officer

Discovery Life Sciences™, the biospecimen and biomarker specialists™, announced that it has acquired Targos Molecular Pathology GmbH, Germany, one of the largest molecular pathology laboratories in Europe, to significantly expand its global tissue biomarker services.

3M’s annual State of Science Index shows as confidence in science grows, 89% of people agree science brings hope and makes the future brighter

Harmony Biosciences Holdings, Inc., a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs, announced the appointment of John C. Jacobs, President and CEO of Harmony, to the Life Sciences Pennsylvania’s Board of Directors, effective May 6, 2021.

Establishment Labs Holdings Inc., a medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, announced that Pratip Dastidar has been appointed Head of Global Operations.

Cognito Therapeutics , a clinical-stage company leading the development of a new class of disease-modifying digital therapeutics to treat neurodegenerative disorders including Alzheimer’s disease, announced today the appointment of Everett Crosland as Chief Commercial Officer.

Sparrow Pharmaceuticals, an emerging clinical-stage biopharmaceutical company developing novel, targeted therapies for disorders of corticosteroid excess, today announced the closing of a $50 million Series A financing.

Rolling submission of BLA to the FDA completed for ciltacabtagene autoleucel (cilta-cel) for the treatment of relapsed or refractory multiple myeloma (RRMM) European Marketing Authorisation Application (MAA) submitted for cilta-cel for the treatment of RRMM